GTx, Inc. is a company of pioneering and driven individuals who are delivering better medicines with new science through established pathways. We are dedicated to the discovery and development of novel, selective small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions.

Our drug development programs are focused on small molecules that selectively modulate the effects of androgens and estrogens.

GTx is developing enobosarm (Ostarine ®; GTx-024), a selective androgen receptor modulator, or SARM, targeted at the androgen receptor, or AR, in women with advanced breast cancer whose tumors express the androgen receptor and the estrogen receptor, or ER, and women with AR positive triple negative breast cancer. Recent clinical studies have also determined that enobosarm builds lean body mass (muscle) in patients with non-small cell lung cancer.

GTx is also developing Capesaris® (GTx-758), a selective ER alpha agonist, as a hormonal therapy for men with advanced prostate cancer.